Impel NeuroPharma said today that the FDA gave it the green light to proceed with its Phase III clinical trial of INP104 – a drug delivered by Impel’s intranasal delivery device for the treatment of acute migraine.
The company expects to start enrolling patients in the pivotal trial in the second half of this year. The study is designed to assess the safety and tolerability of long-term, intermittent use of the drug-device combination therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post Impel NeuroPharma readies trial for intranasal drug-device migraine treatment appeared first on MassDevice.